Opinion|Videos|May 21, 2025
CABINET Trial: Study Design and Patient Population
Author(s)Thorvardur R. Halfdanarson, MD
A panelist discusses how the CABINET trial was a National Cancer Institute (NCI)–supported study conducted by the Alliance for Clinical Trials in Oncology that enrolled patients with well-differentiated grade 1 through 3 pancreatic or extrapancreatic neuroendocrine tumors who had progressed after somatostatin analogue therapy and at least 1 other FDA-approved therapy.
Advertisement
Video content above is prompted by the following:
The CABINET Trial Design and Significance
Key Themes:
- Trial Design:
- NCI-supported study run through the Alliance for Clinical Trials in Oncology network
- Included well-differentiated grade 1, 2, or 3 pancreatic or extrapancreatic neuroendocrine tumors
- Required disease progression after somatostatin analogue therapy and at least 1 other FDA-approved therapy
- 2:1 randomization to cabozantinib vs placebo with crossover option
- Trial Significance:
- Rigorously conducted through academic institutions and large community practices
- Particularly important for demonstrating active therapy post radioligand therapy
- Protocol modifications improved accrual rates as the trial progressed
Notable Insights:
Dr Halfdanarson emphasized that the CABINET trial provides valuable evidence for treatment options following radioligand therapy with lutetium-177 dotatate, addressing a knowledge gap in the field.
Advertisement
Related to this article
The application is supported by the phase 3 SAFFRON trial, in which savolitinib plus osimertinib improved progression-free and overall survival vs chemotherapy.
Proton therapy did not improve overall survival vs photon therapy in advanced hepatocellular carcinoma in the phase 3 NRG-GI003 trial.
Published findings from the ASPEN-06 trial of evorpacept in previously treated HER2+ gastric cancers included exploratory analyses suggesting CD47 is a predictive biomarker for benefit with the targeted agent.
Benjamin Herzberg, MD, discusses KRAS-mutant non–small cell lung cancer, upfront biomarker testing, and the emerging RAS inhibitor toolkit on Targeted Talks.
Clinicians weigh RCC immunotherapy choices by risk, metastasis site, and histology, citing durable outcomes with nivo-ipi and favoring TKIs after early progression.
Published phase 1 findings support the promising efficacy and tolerability of anito-cel in relapsed/refractory multiple myeloma, explains lead author Matthew Frigault, MD.
The FDA communicated that the phase 2 IDeate-Lung01 results were not sufficient for an accelerated approval of I-DXd in small cell lung cancer.
Broad oncology bundles falter; experts push smaller surgery/radiation episodes, better navigation, and AI analytics to improve value-based care.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Anito-Cel Delivers Durable Responses With Low Neurotoxicity in RRMM
2
Risk, Histology, and Metastatic Site Guide First-Line RCC Treatment Choices
3
FDA Application Withdrawn for I-DXd in Small Cell Lung Cancer
4
Elinzanetant Gets Priority Review for VMS From Breast Cancer Endocrine Therapy
5